Skip to main
EKSO

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc demonstrated a strong financial recovery in the third quarter of 2025, reporting total revenues of $4.22 million, which marked a significant increase of 105% quarter-over-quarter from the previous quarter's $2.06 million. The company also experienced an improvement in gross margins, rising to 60.3% compared to 39.8% in the second quarter of 2025, indicating enhanced operational efficiency. Furthermore, the announcement of a non-binding merger agreement with Applied Digital Cloud suggests potential for strategic growth and expansion, enhancing the overall positive outlook for Ekso Bionics in the healthcare and industrial exoskeleton technology markets.

Bears say

Ekso Bionics Holdings Inc experienced a revenue shortfall in the previous quarter, primarily attributed to two significant order delays in its Enterprise Health segment, resulting in a missed consensus expectation by $1.5 million. The company reported revenues of $4.23 million in 3Q25, with a net loss of $0.54 per share, which, while slightly better than the consensus estimate, still indicates ongoing financial challenges. Additionally, the downgrade to a Neutral rating and the removal of a previous price target reflect growing concerns about the company's ability to stabilize and grow its revenue amid these operational setbacks.

EKSO has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 2 analysts, EKSO has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.